Outlook Therapeutics Inc【OTLK】株式ニュース

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 8-K - Current report

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

techno53 3日前

Who is the AH pulling the PPS down???

👍️0

Whalatane 5日前

Lytenava and Avastin contain the same active core biological molecule (bevacizumab), but they are not exactly the same product.

While they target wet age-related macular degeneration (wet AMD) in the exact same biological way, they differ fundamentally in their formulation, manufacturing regulations, and approval status.

Core Differences Between Lytenava and Avastin
Active Ingredient:
Both drugs utilize bevacizumab, an anti-VEGF monoclonal antibody that slows down the growth of abnormal, leaking blood vessels in the back of the eye

.Approval and Intent:
Avastin was originally designed and approved by regulatory bodies as an intravenous cancer treatment.
Using it for wet AMD is considered an "off-label" use.

Lytenava (bevacizumab gamma / bevacizumab-vikg) was specifically developed, formulated, and packaged exclusively for direct injection into the eye (ophthalmic use
---------------------
MD's want to prescribe on label drugs , not off label ...because of legal risk exposure

JMO
Kiwi

👍️0

Whalatane 5日前

Well since I have some time waiting for the FDA decision on UNCY's OLC ...I'll convey my thoughts on OTLK .

There are roughly 3m shots of off label Avastin used each year in the US for Wet AMD .
MD's would much rather prescribe on label ( approved ) Avastin for wet AMD . It removes their legal risk exposure .
There is a minor risk of contamination from the compounded off label use of Avastin .....No MD wants that risk if they can prescribe FDA approved Avastin for Wet AMD

Use in the UK as Lytenava

Lytenava vs. Eylea:
At a list price of £470, Lytenava saves the NHS nearly £350 per injection compared to Eylea (£816). Over a standard course of treatment (roughly 8 to 9 injections in the first year), switching to Lytenava can save thousands of pounds per patient

.Lytenava vs. Lucentis:
Lytenava undercuts Lucentis by roughly £80 per dose at face value. However, NICE reports that clinical trial data shows Lytenava actually achieves better vision outcomes for many patients compared to Lucentis, making it a superior choice for both cost and efficacy.

So thats the market they want access to .
The risks ...beyond risk FDA declines to approve ( maybe 20-30% chance they don't ) is the expected dilution from their recently approved $100m ATM .
If approved expect significant dilution as Co raises cash ( currently only around $7.75 m ) to fund the launch of Lytenava ( their on label Avastin )

So this may very well be a " sell the news " event ( approval ) until the smoke clears from the expected immediate dilution following approval .
JMO
This is just a quick take .
Havent done a ton of DD
Small position

Kiwi

👍️0

techno53 5日前

OTLK would be smart to wait on any reverse split until the PPS reaches at least $6. That way the amount of shares the company will need for future expenses will be far less than the 600,000,000 that was proposed.

👍️0

ErnieBilco 5日前

Personally I think the RS is less likely to happen since they are now listing compliant as of Friday, don't get me wrong they may still do one but it would be on the smaller end of the range - just my WAG

👍️0

WizardSanctuary18 5日前

Hi everyone 🙂Genuinely, I’m interested in OTLK and I did some macro and DD and I’m actually thinking of opening a position, but I still see a few clear overhangs.

The July 16 shareholder vote is a big one for me. Warrants, authorised share increase and reverse split authority all point to dilution risk, especially when the company still needs cash. So even if the FDA setup looks better now, I’m not sure the stock gets a clean run without financing pressure sitting over it.

Commercially, I also think the bigger question is not just approval, but adoption. Avastin is already widely used off label, and then you’ve got entrenched competition like Eylea, Vabysmo and Lucentis. So Lytenava may have a regulatory/on-label advantage, but I still want to understand how much real market share it can take.

Also, the stock has already had a massive move, so risk/reward is not as simple as it was before the pop.

Happy to hear your thoughts case if I’m missing something 🙏

👍️ 1

shurtha2000 6日前

Pondering on the FDA characters who issued the 3 CRL's for OTLK and I'm wondering are these the same people who issued the 3 CRL's to ALDX and are no longer there for the next meeting
Something to think about

👍️0

ErnieBilco 6日前

As previously reported, on February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing
Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq staff had determined to delist the
Company’s common stock, par value $0.01 per share (the “Common Stock”) from the Nasdaq Capital Market because it failed to maintain a minimum bid
price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2).
On June 26, 2026, the Company received a letter from the Nasdaq Staff notifying the Company that, because the closing bid price of the Company’s common
stock had been at $1.00 per share or greater for the ten consecutive business days between June 11, 2026 - June 25, 2026, the Company had regained
compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market and that
this matter is now closed.

https://www.otcmarkets.com/filing/conv_pdf?id=19569075&guid=DtF-kajPKB2peih

👍️0

Stumblebum 1週前

Once Uncy pops 🤞…. I’m selling some and loading up on more of Otlk

👍️0

glenn1919 1週前

OTLK.................https://stockcharts.com/sc3/ui/?s=OTLK&p=w&b=5&g=0&id=p86431144783

👍️0

ErnieBilco 1週前

Always nice to see new old faces in Ernieville

😂 1

Whalatane 1週前

Well you , Ernie and Wizard have forced me to do more DD on OTLK.
My fav in the space is KOD but what I'm reading in the UK is that their health system wants patients prescribed OTLK's eye drug first , have them fail on that , before paying for Eyelea .
OTLK costs the UK health system about $600 a shot and Eyela about $2k ...however Eylea lasts twice as long .
Small position but looks good for approval in the US late July
JMO
Kiwi

👍️ 1

techno53 1週前

I wish the PPS would go over $2.00 soon.

Yesterday was 10th day over a buck

👍️0

techno53 1週前

Who is the SOB pulling the PPS down???

👍️0

techno53 1週前

Let the PPS run up and quit pulling it down, shorts!!! This stock should be over $2.00 today!!

👍️0

techno53 1週前

Let the PPS run up!!! I hope the shorts get pounded on the next run up!!

👍️0

Tom turtles 2週前

What a monster.....Holding 50k from .,28

To the moon Alice.. YEEHA

👍️0

glenn1919 2週前

OTLK..........................https://stockcharts.com/sc3/ui/?s=OTLK&p=w&b=5&g=0&id=p86431144783

👍️0

techno53 2週前

Let the PPS run up !!

👍️0

WizardSanctuary18 2週前

Some good learnings for me! Thanks Ernie! 🙏

👍️0

ErnieBilco 2週前

The 1st thing I look at in the morning is what stocks have been beaten down at least 50% and then I'll look for the reason, many times it is caused by a stock offering - if that's the case I take the offering price and deduct 30% and if it looks fair to me I BUY IT - NOT A LOT BUT ENOUGH TO GET MY EYES ON IT AND THEN ADD OR JUST KEEP WHAT I GOT UNTIL SOMETHING CHANGES MY MIND.

It works out well in about 80% of the time other times I have to average down if the drop continues without any real reason other than the offering.

There are just so many ways to find stocks you like for whatever reason..... MINE IS MAKING MONEY, so I shoot low and if I catch some shares great if I don't - tomorrow will have new beaten down tickers. I'm too busy to dig into the weeds, I manage 9 family accounts with probably 100s of tickers(some the same and other hold different tickers).

I started with penny stocks in 2009 and the past couple of years I've moved into medical and biotech heavily.

Best ever trade to date: RLLCF bought a total of $85.95 @ .0001 and sold 2 months later for just over $60K - I WASH EXTREMELY SURPRISED BUT IT WAS ALL ABOUT TIMING. TO THIS DAY I CONTINUE TO HOLD SHARES FOR A POSSIBLE RUN AGAIN. I also own RYCEF and RYCEY around .80-$1. and they are currently over $18 - I could bank over $80K if I sold today but I have a $25 target and I'm willing to stick to it.

It's my hobby and a game I really really enjoy.

👍️ 1

WizardSanctuary18 2週前

Haha fair enough, I respect that. Sometimes the numbers and setup matter more than the story.

I’m probably the opposite, I end up digging into the weeds too much😅

👍️0

ErnieBilco 2週前

See that's the thing - I don't dig into the weeds - I simply buy what I believe are beaten down stocks, never overload anything and just let them stagnate or rise when they are ready.

I can't even tell you what they do all I know is the FDA admitted their screwup in regards to this ticker.

I'm a numbers guy and the stories really mean very little to me.

Wish I could have been more informative here but it is just like almost all the others I hold very few had a story that impressed me.

Stumble, Kiwi, Rosemount and others are the DD investors I just love the game, SLS I'm up over 1307.34% and still have a long way to $25 or better

👍️0

WizardSanctuary18 2週前

Thanks Ernie… Wow, that’s a great entry. 246% up is seriously impressive.

Genuine question, what gives you the strongest conviction here from the commercial side?

I’m starting to understand the bull case better, but still trying to pressure test a few things: how Lytenava is priced versus compounded Avastin, how much 503B/503A compounding pressure really helps, whether payers push it as a cleaner approved option, and how it competes with Eylea/Eylea HD, Vabysmo and biosimilars.

Also curious how you think about the dilution/launch funding risk if approval comes.

Appreciate your views. Just trying to understand what assumptions you’re using for market share, pricing and upside from here.

👍️0

ErnieBilco 2週前

The more you venture into bio tickers the more you will see of me - I like to get in before they take off,

This one is developing nicely for me, currently up 246.77%

👍️0

WizardSanctuary18 2週前

Happy to see you here as well Ernie!

👍️0

ErnieBilco 2週前

Normal when pumpdy dumpdy leaves

It will return to its upward trend but market is closed tomorrow so profit taking is expected

👍️0

techno53 2週前

What is pulling this stock down??? The PPS should still be climbing!!!

👍️0

ErnieBilco 2週前

Why would I short it if I think it is going to multi dollars?

I don't understand.

👍️0

Golden Bear 86 2週前

You should short it then

👍️0

ErnieBilco 2週前

Doubt it since the FDA said they screwed it up not the company.

👍️0

Tom turtles 2週前

4th time, 5th time...gonna fail again

👍️0

glenn1919 2週前

otlk.................................p/m

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision

June 16, 2026

• Outlook Therapeutics said it has already started pre-launch activities.

• The FDA refused to approve LYTENAVA in December, but later determined that no additional clinical trials would be required following the company's appeal.

• If approved, Lytenava would become the first and only FDA-approved ophthalmic formulation of bevacizumab.

Shares of Outlook Therapeutics, Inc. (OTLK) jumped 28% on Tuesday after the company announced today that the U.S. Food and Drug Administration has accepted its resubmitted biologics license application for LYTENAVA as a treatment for wet age-related macular degeneration (wet AMD).

The agency will now decide whether to approve the drug by July 29, 2026. The company has already begun pre-launch activities.

See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox

OTLK's Long Regulatory Road
The FDA had refused to approve the drug in December. Outlook Therapeutics appealed the decision, and the FDA Office of New Drugs subsequently concluded that no additional trials are required, stating that substantial evidence of effectiveness has already been established. The agency instead directed the review division to focus on final product labeling, and the company resubmitted its application earlier this month.

The company's original application was accepted by the FDA in October 2022. In August 2023, the agency issued its first letter refusing approval, citing Chemistry, Manufacturing and Controls (CMC) deficiencies, observations from pre-approval manufacturing inspections, and insufficient substantial evidence of effectiveness.

Outlook responded by addressing the manufacturing issues and, in early 2025, resubmitted the application. The FDA accepted it in April 2025, but the agency denied its approval again in late 2025, this time focusing on a perceived lack of confirmatory efficacy evidence and recommending additional data.

If approved, Lytenava would become the first and only FDA-approved ophthalmic formulation of bevacizumab, an antibody medication used to treat various solid tumors and specific eye diseases. The product is already approved in the European Union and the United Kingdom for wet AMD, a severe, progressive eye condition where abnormal blood vessels grow uncontrollably under the retina. These fragile vessels leak fluid and blood, causing rapid and often irreversible central vision loss if left untreated.

How Did OTLK Retail Traders React?
On Stocktwits, retail sentiment around OTLK stayed within the 'extremely bullish' territory over the past 24 hours, while message volume increased from 'high' to 'extremely high' levels.

A Stocktwits user highlighted that the company has already begun pre-launch activities.

Others voiced hopes for a major rally on approval for the drug.

According to Koyfin data, two of the four analysts covering OTLK rate it 'Buy,' while the other two rate it a 'Hold.' The 12-month average price target on the stock is $5.50, representing a potential upside of 374% from the stock's last close.

OTLK stock has gained 126% this year.

Link article

$OTLK 🗞️

The rocket ship has launched. To the moon Alice...

👍️0

glenn1919 3週前

OTLK................................https://stockcharts.com/sc3/ui/?s=OTLK&p=w&b=5&g=0&id=p86431144783

👍️0

glenn1919 3週前

OTLK......................................p/m

👍️0

georgie18 3週前

OTLK...$1.29...🥳...Off my .33 Gap Fill Alert...

georgie18

Re: georgie18 post# 1539

Thursday, June 11, 2026 10:56:42 AM

Post#
1540
of 1546
OTLK...$1.03...🥳...Bullish Psar Flip off my .33 Alert...

georgie18

Re: None

Thursday, June 11, 2026 6:25:06 AM

Post#
724968
of 725007
OTLK...97...🥳... Off my .33 Gap Fill Alert...

georgie18

Re: georgie18 post# 1500

Tuesday, June 02, 2026 7:18:19 AM

Post#
1511
of 1538
OTLK...90...🥳...Off my .33 Gap Fill Alert...

georgie18

Re: georgie18 post# 1496

Friday, May 29, 2026 9:43:04 AM

Post#
1500
of 1510
OTLK...80s starting here...🥳...Off my .33 Gap Fill Alert...

georgie18

Re: georgie18 post# 1493

Thursday, May 28, 2026 1:37:30 PM

Post#
1496
of 1499
OTLK...747...🥳...Off my .33 Gap Fill Alert...Break/Hold .98 and she will fill the $2 gap...imo... we shall see...

georgie18

Re: georgie18 post# 1492

Thursday, May 28, 2026 9:09:22 AM

Post#
1493
of 1495
OTLK...64...🥳...Off my .33 Gap Fill Alert...

georgie18

Re: georgie18 post# 1473

Wednesday, May 27, 2026 3:25:44 PM

Post#
1492
of 1492
OTLK...53s Clearing here...🥳

georgie18

Re: georgie18 post# 1442

Tuesday, May 26, 2026 8:35:26 AM

Post#
1473
of 1491
OTLK...4741...🥳...Still holding .20 range shares...

georgie18

Re: georgie18 post# 1441

Monday, April 20, 2026 3:48:51 PM

Post#
1442
of 1472
OTLK...3730...🥳

georgie18

Re: georgie18 post# 1439

Monday, April 20, 2026 9:36:17 AM

Post#
1441
of 1441
OTLK...3570...🥳

georgie18

Re: None

Monday, April 20, 2026 7:57:55 AM

Post#
1439
of 1440
OTLK...33... 🥳...Gap Filled... https://schrts.co/CSihjJqh ...Looking for Upper Bollie Breakout here...

$1.62 after hours.....ya baby

👍️0

Shadonnie 3週前

Outlook Therapeutics shares are trading higher after Ascendiant Capital raised its price target on the stock from $6 to $10

👍️0

ErnieBilco 3週前

Just needs over a buck for 10 trading days then they are good

👍️0

techno53 3週前

Waiting for FDA approval on drug license.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Outlook Therapeutics Inc (OTLK)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

Outlook Therapeutics Inc (OTLK) ニュース

Form 8-K - Current report

Form 8-K - Current report

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

OTLK Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Outlook Therapeutics Inc (OTLK)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

Outlook Therapeutics Inc (OTLK) ニュース

Form 8-K - Current report

Form 8-K - Current report

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

OTLK Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する